MFS
PGNX

MSI Financial Services’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

MSI Financial Services’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$9K Hold
1,000
– – ﹤0.01% 2882
2016
Q3 		$6K Hold
1,000
– – ﹤0.01% 3082
2016
Q2 		$4K Buy
+1,000
New +$4.83K ﹤0.01% 3283

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MSI Financial Services's PGNX Position: Q4 2016 in Review

MSI Financial Services held its Progenics Pharmaceuticals Inc (PGNX) position steady in Q4 2016 at 1,000 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #2882.

MSI Financial Services first reported a position in PGNX in Q2 2016 and has held it in 3 quarters since. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • MSI Financial Services held 1,000 shares of Progenics Pharmaceuticals Inc worth $9K as of Q4 2016.
  • MSI Financial Services left its Progenics Pharmaceuticals Inc share count unchanged in Q4 2016.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #2882 holding.
  • MSI Financial Services first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and has held it in 3 quarters since.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.